Upstream Bio, Inc.(UPB) - 2025 Q2 - Quarterly Results

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress Upcoming Milestones and Recent Business Highlights • Two key upcoming top-line readouts: o Top-line data from the VIBRANT Phase 2 trial in patients with CRSwNP expected in the third quarter of 2025: VIBRANT is a Phase 2 global, randomized, double-blind, placebo-controlled, parallel group clinical trial designed to assess the efficacy and safety of verekitug in participants with CRSwNP, dosed every 12 weeks. Patient ...